BIOTECH, STOCKS, TECHNOLOGY

John McCamant

Editor,

Medical Technology Stock Letter

  • #1 Portfolio Performance of >500 by Hulbert’s Financial Digest in 2013
  • 2018 MoneyShow Top Pick MDGL up 575% ($15.96-91.79)
  • 2019 MoneyShow Top Pick MDCO up 457% ($18.57-84.90)

About John

John McCamant was named editor of the Medical Technology Stock Letter in August 2000. He has spent 35 years on the front lines of biotechnology investing as an equities analyst and in venture capital. His expertise in biotechnology investments is a subject of media interest, and he is frequently consulted and quoted by The Washington Post, BusinessWeek, Reuters, and Bloomberg.

John's Articles

The FDA approved Lybalvi from Alkermes Plc (ALKS) for the treatment of schizophrenia and bipolar I disorder on the June 1 PDUFA date, notes John McCamant, editor of The Medical Technology Stock Letter — and a participant in the MoneyShow July 13-15 Virtual Expo. Register here for free.
Vaxart (VXRT) is a leader in developing an oral vaccine for COVID-19 that would make it significantly easier to vaccinate the world, notes biotech sector expert John McCamant, editor of The Medical Technology Stock Letter.
Esperion (ESPR) recently announced the appointment of Sheldon Koenig as president and chief executive officer and board member, effective immediately, notes John McCamant, biotech sector expert and editor of The Medical Technology Stock Letter.
Myovant Sciences (MYOV) recently reported their earnings and the first peek at Orgovyx sales with their partner Pfizer (PFE), reports John McCamant, editor of The Medical Technology Stock Letter.

John's Videos

Biotech Covid-19 vaccine development has demonstrated the power of biotech to change the world and make handsome returns for investors. With the Delta variant wrecking devastation worldwide, join this presentation to discover what's next. Can an oral vaccine be the difference maker to finally tame Covid-19?
Biotech Covid-19 vaccine development has demonstrated the power of biotech to change the world and make handsome returns for investors.
Biotech is providing innovative drugs and vaccines for Covod-19. Join John McCamant of the Medical Technology Stock Letter to help you identify the winners.
John McCamant, editor of The Medical Technology Stock Letter, is known for helping investors pick biotech winners. Join this session to discover a unique investment opportunity in a repurposed Phase II pill, poised to treat Covid-19 by reducing viral load.



Newsletter Contributions

Medical Technology Stock Letter

The Medical Technology Stock Letter (“MTSL“) is published 24 times per year and offers unique perspectives on medical trends, portfolio companies and focus on diversification and risk management strategies to help investors profit from today’s market volatility.

Learn More
Live Now

Accredited Investors Virtual Expo

July 27 - 29, 2021